Psyched Wellness (CSE: PSYC) has completed the first step in identifying the medicinal potential of Muscimol for both mental and physical health issues. The announcement was made by the company this morning, following the completion of research by Professor David Nutt, whom is head of the firms scientific committee.
The study on Muscimol, which began in December, was initiated as a means of compiling and reviewing scientific papers that discussed the use of the compound. Such work was conducted to build scientific evidence to support the firms thesis that Muscimol can serve as a potential treatment for various mental and physical health issues.
In commenting on the study, Nutt indicated that potential uses of the compound include treatment for health issues that include insomnia and sleep disorders, pre-menstrual syndrome, and pain. The compound reportedly offers exciting opportunities for these conditions as a result of the recently discovered GABA-A receptor, and how Muscimol interacts with it.
“We are very excited to share this development, completing this research will help the company determine what ailments will be the focus of our research with the goal of taking it to a full clinical trial.”
David Shisel, COO of Psyched Wellness
Psyched Wellness last traded at $0.28 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
